Reply  by Felker, G. Michael et al.
Felker et al. (2) do not consider that anemia can be a normal
adaptation to increased cardiovascular demand. Both athletic
training (3–5) and pregnancy (6) cause a simultaneous increase in
TBH and PV, with the increase in PV being relatively greater than
the increase in TBH (3–6). This results in an increased total blood
volume, reduced blood viscosity, and anemia—an adaptation that
potentially enhances total-blood oxygen-carrying capacity, while
concurrently decreasing blood viscosity (6,7).
Although not widely studied in heart failure, the importance of
blood viscosity was given little consideration by Felker et al. (2). At
a fixed hematocrit, cardiac output is enhanced as blood viscosity
decreases (8). Blood viscosity is also inversely related to physical
performance in athletes (7). Anemia in heart failure is undoubtedly
the end result of multiple pathological pathways (2). However, a
possible physiologic benefit (reduced blood viscosity) should not be
discounted, and the broader consequences of increased blood
viscosity from erythropoietin (EPO) therapy require careful con-
sideration.
Felker et al. (2) provided little information on the impressive
direct cardioprotective actions of EPO (9). Furthermore, research
published after the Felker et al. (2) study appeared suggests that,
from an evolutionary perspective, cardioprotection was one of
EPO’s original functions (10), and derivatives of EPO, devoid of
an erythropoietic action, retain tissue-protective effects (11).
Despite positive results in small studies (2), the large, random-
ized Normal Hematocrit Treatment trial of EPO in anemic
dialysis patients with cardiac disease was largely negative (12). This
should serve as a cautionary note, and the notion that the
appropriate attitude toward EPO therapy in heart failure is “a
mixture of optimism and caution” (2) needs expanding. It is
difficult to reconcile EPO therapy in anemic patients with normal
TBH but with expanded PV. Given the potentially adverse
consequences of EPO (increased blood viscosity and other detri-
mental sequelae [2]) it would seem prudent to initially restrict
human trials of EPO in heart failure to patients with decreased
TBH.
Finally, EPO or its derivatives are a promising potential
adjunctive therapy for heart failure, but to realize this potential a
meticulous and rigorous approach is imperative.
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REPLY
We appreciate the interest of Drs. Kovacic and Cheng in our
report (1) on the relationship between heart failure and anemia.
We agree on the need for careful assessment of risks and benefits
when evaluating any new therapeutic approach in heart failure. Dr.
Kovacic correctly points out that anemia is technically the result of
a decrease in red blood cell mass rather than a decreased hemo-
globin concentration (2). Because accurate quantification of red
cell mass requires labeled red blood cell scanning, hemoglobin
concentration is frequently employed as a readily available surro-
gate in clinical practice. We concede that in states of plasma
expansion (such as heart failure, renal failure, or pregnancy),
hemoglobin concentration may not accurately reflect red blood cell
mass. Our use of the terms “true anemia” and “hemodilution”
reflected the terminology used in the study by Androne et al. (3),
and we believe this nomenclature accurately describes the two
mechanisms for decreased hemoglobin concentration described
above.
Dr. Kovacic’s assertion that decreased hemoglobin concentra-
tion from plasma expansion in patients with heart failure may
represent a “normal adaptation to increased cardiovascular de-
mand” that has a “possible physiologic benefit (reduced blood
viscosity)” is not supported by the data from Androne et al., which
demonstrated a worse prognosis in patients with “hemodilution”
compared to those with “true anemia” (3).
Both Drs. Cheng and Kovacic cite the potentially important
role of blood viscosity in understanding the cardiovascular effects of
anemia. Dr. Cheng appropriately points out that very elevated
hematocrit levels (generally 50%) are associated with increased
blood viscosity, which could potentially increase the risk for
ischemic cardiac events. However, the studies by Burch and
DePasquale cited by Dr. Cheng evaluated “bloodletting” in pa-
tients with hematocrit in the upper range of normal or above
normal (almost always 50%) (4–6). In contrast, preliminary
therapeutic studies using erythropoietin analogs in heart failure
have generally targeted a modest rise in hemoglobin with a goal
hemoglobin corresponding to a hematocrit below 40% (7,8).
Notably, this is still well below the target hematocrit from
phlebotomy suggested by Burch of 45% for men and 42% for
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women (4). Although in vivo evaluation of blood rheology is
difficult, in vitro data suggest that optimal oxygen delivery (bal-
ancing oxygen delivery and blood viscosity) occurs at hematocrit
levels between 38% to 51% (9).
Importantly, different therapies addressing the same target may
be associated with a different balance of risks and benefits, and
therapies may exert therapeutic or harmful effects through path-
ways unrelated to their presumed mechanisms. As Dr. Kovacic
points out and as we stated in our review, emerging data suggest a
role for erythropoietin in cardioprotection from ischemic injury.
Such data raises the possibility that erythropoietin analogs may
have beneficial effects in cardiovascular disease that are distinct
from their effects on erythrogenesis. Conversely, recently published
data suggest that red blood cell transfusions are associated with an
increase of ischemic events in patients with acute coronary syn-
dromes, possibly due to lack of ability of stored erythrocytes to
effectively donate nitric oxide in the microvasculature (10). Given
the uncertain balance of risks and benefits of therapy with
erythropoietin analogs in patients with heart failure, the clinical
equipoise required to proceed with carefully controlled, appropri-
ately powered randomized trials clearly exists. As we stated in our
conclusions, we continue to believe “a mixture of optimism and
caution” is the appropriate stance until results from such trials are
available.
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Conflation of Empiric and Nonempiric
Truths in Cardiovascular Guidelines
The newly published guidelines for the treatment of ST-elevation
myocardial infarction (STEMI) use the more detailed definitions
of classes of recommendations and levels of evidence as shown in
Table 1 of the report (1). Unfortunately, this system continues to
conflate empiric and nonempiric information, despite the fact that
these issues are incommensurable and should not be reflected
within a single evidentiary hierarchy system. The result of this
commingling is that nonempiric facts are erroneously assigned to
the lowest level of certainty. These assignments reflect confusion
between those instances where evidence is subject to, but has yet to
be, scientifically tested, and those instances wherein the truth of
the statement cannot be empirically proven. For example, the Class
I recommendation regarding the need for an electrocardiogram
(ECG) is considered a matter of expert consensus, and though this
is true, the consensus does not pertain to an experimentally based
question but rather to the current definition of the disease state
being discussed. The ECG is the sine qua non of STEMI. All
experimentation presupposes this definition. Until the definition is
amended or the measurement tool changed, the certainty that an
ECG is needed is absolute. This is a nonempiric statement that
does not need to be, nor can it be, experimentally proven. Its
certainty is parallel to, not subordinate to, the best experimental
data.
Similarly, the Class III recommendation not to do coronary
angiography on patients where the risks of revascularization
outweigh the benefits reflects the nonempiric moral dictum to do
no harm. This is a concept that is not open to experimental proof,
but is an absolute that forms the basic fabric of our profession.
Many other examples of undervalued nonempiric statements
appear throughout cardiovascular guidelines. Future task forces/
writing groups need to recognize that nonempiric concepts should
be separated from empiric concepts and that nonempiric data
represent levels of certainty that are parallel to, not subordinate to,
empiric data.
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